| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/27/2013 | WO2013091657A1 Therapeutic applications of calcium electroporation to effectively induce tumor necrosis |
| 06/27/2013 | WO2013091539A1 Pyrrole six-membered heteroaryl ring derivative, preparation method therefor, and medicinal uses thereof |
| 06/27/2013 | WO2013091507A1 Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof |
| 06/27/2013 | WO2013091502A1 Tri-heterocyclic derivatives, preparation process and uses thereof |
| 06/27/2013 | WO2013091361A1 Cycloheptapeptide and use thereof in preparation of anti-tumour drugs |
| 06/27/2013 | WO2013091293A1 Medicine which relates to human gene nlk and use thereof |
| 06/27/2013 | WO2013091283A1 Pharmaceutical compositions of triptorelin microspheres |
| 06/27/2013 | WO2013091082A1 Bis-(aryl/heteroaryl)-methylene compounds, pharmaceutical compositions containing same and their use for treating cancer |
| 06/27/2013 | WO2013091052A1 Molecular compound comprising an acridine molecule chemically linked to a carboxylic group, which can be used for the selective destruction of solid tumour cells |
| 06/27/2013 | WO2013066134A3 Novel cinnamyl-rhodanine derivatives and pharmaceutical composition comprising same as active ingredients |
| 06/27/2013 | WO2013064919A9 Quinazoline derivatives with hsp90 inhibitory activity |
| 06/27/2013 | WO2013061328A8 Methods of treating cancer |
| 06/27/2013 | WO2013061083A3 Therapeutic agents and uses thereof |
| 06/27/2013 | WO2013058482A3 Multi-functional nucleic acid-based anti-cancer drug capable of targeting and therapy, method for preparing same and anti-cancer composition comprising same |
| 06/27/2013 | WO2013056108A3 Solid dispersions of a erb2 (her2) inhibitor |
| 06/27/2013 | WO2013053034A3 Thiazacridines used in anti-cancer therapy |
| 06/27/2013 | WO2013034979A3 Crystalline forms of cabazitaxel |
| 06/27/2013 | WO2012159754A3 Individualized vaccines for cancer |
| 06/27/2013 | WO2012116225A9 Muc1 based glycolipopeptide vaccine with adjuvant |
| 06/27/2013 | US20130165634 Expression and export of angiogenesis inhibitors as immunofusins |
| 06/27/2013 | US20130165503 Method for Treating Ocular Neovascularization |
| 06/27/2013 | US20130165458 Quinazoline compounds as kinase inhibitors |
| 06/27/2013 | US20130165457 Inhibitors of e1 activating enzymes |
| 06/27/2013 | US20130165424 Dispiropyrrolidine derivatives |
| 06/27/2013 | US20130165419 Combination anti-inflammatory ophthalmic compositions |
| 06/27/2013 | US20130165405 Cyclodextrin-based polymers for therapeutics delivery |
| 06/27/2013 | US20130165380 Administration of an antagonist of a5ß1 for anti-angiogenesis and cancer treatment |
| 06/27/2013 | US20130164843 Method and medicament for inhibiting the expression of a given gene |
| 06/27/2013 | US20130164387 Novel mannopyranoside derivatives with anticancer activity |
| 06/27/2013 | US20130164366 Method and medicament for inhibiting the expression of a given gene |
| 06/27/2013 | US20130164255 Immunotherapy for reversing immune suppression |
| 06/27/2013 | DE102010014260A1 Treating e.g. cancer and multiple sclerosis in humans or animals, comprises placing patient into artificial coma, and treating tumors, abnormal cells and/or disease caused by optimized protein-free or very low-protein extreme fasting cure |
| 06/27/2013 | CA2858963A1 Vaccines against hpv |
| 06/27/2013 | CA2858123A1 [1,2,4]triazolopyridines and their use as phospodiesterase inhibitors |
| 06/27/2013 | CA2858099A1 E-selectin antagonist compounds, compositions, and methods of use |
| 06/27/2013 | CA2858090A1 Pharmaceutical compositions and methods for treating gastrointestinal infections and disorders |
| 06/27/2013 | CA2857977A1 Pyrrole six-membered heteroaryl ring derivative, preparation method thereof, and medicinal uses thereof |
| 06/27/2013 | CA2857490A1 Guanine analogs as telomerase substrates and telomere length affectors |
| 06/27/2013 | CA2856964A1 Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals |
| 06/27/2013 | CA2856448A1 Novel heterocyclic carboxamides as modulators of kinase activity |
| 06/27/2013 | CA2855764A1 Tri-heterocyclic derivatives, preparation process and uses thereof |
| 06/27/2013 | CA2854248A1 2,4-diamine-pyrimidine derivative as serine/threonine kinase inhibitors |
| 06/26/2013 | EP2607367A1 Glycerol phenyl butyrate derivatives |
| 06/26/2013 | EP2607366A1 Glycerol phenyl butyrate esters |
| 06/26/2013 | EP2607358A1 Novel anti-inflammatory metabolite derived from omega-3-type fatty acid |
| 06/26/2013 | EP2607348A2 Plasminogen Activator Inhibitor-1 Inhibitor |
| 06/26/2013 | EP2606933A2 Combination of an IAP-inhibitor and a taxane |
| 06/26/2013 | EP2606911A1 Receptor And Antigen Targeted Prodrug |
| 06/26/2013 | EP2606909A1 Method and composition for treating, preventing and diagnosing cancer containing cancer stem cells or derived therefrom |
| 06/26/2013 | EP2606890A1 Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer |
| 06/26/2013 | EP2606889A1 Substituted Thiazoles as VEGFR2 kinase Inhibitors |
| 06/26/2013 | EP2606886A1 Composition containing tetracyclic compound |
| 06/26/2013 | EP2606884A1 Inhibitors of notch signaling pathway and use thereof in treatment of cancers |
| 06/26/2013 | EP2606137A2 Anti-cancer adenoviruses |
| 06/26/2013 | EP2606133A1 Suv420h1 and suv420h2 as target genes for cancer therapy and diagnosis |
| 06/26/2013 | EP2606070A1 Antibodies for epidermal growth factor receptor 3 (her3) |
| 06/26/2013 | EP2606069A1 Humanized anti-interleukin 3 receptor alpha chain antibodies |
| 06/26/2013 | EP2606068A1 Combined use of fc gamma riib (cd32b) and cd20 - specific antibodies |
| 06/26/2013 | EP2606051A1 Pyrrolopyrimidine compounds and uses thereof |
| 06/26/2013 | EP2606050A2 Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors |
| 06/26/2013 | EP2606044A1 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
| 06/26/2013 | EP2606034A1 Pyrimidine derivatives as fak inhibitors |
| 06/26/2013 | EP2606031A2 Autotaxin inhibitors and uses thereof |
| 06/26/2013 | EP2606021A2 1,5-diphenyl-penta-1,4-dien-3-one compounds |
| 06/26/2013 | EP2605800A1 Process for producing radiohalogenated bioconjugates and products thereof |
| 06/26/2013 | EP2605797A2 Therapeutic peptide-polymer conjugates, particles, compositions, and related methods |
| 06/26/2013 | EP2605788A2 Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases |
| 06/26/2013 | EP2605783A1 Oncolytic measles virus |
| 06/26/2013 | EP2605775A1 Treatment of liver cancer |
| 06/26/2013 | EP2605767A1 Ship1 modulators and related methods |
| 06/26/2013 | EP2605766A2 Novel combination therapy for the treatment of cancer |
| 06/26/2013 | EP2605764A1 Combination anti - cancer therapy |
| 06/26/2013 | EP2605650A2 Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol |
| 06/26/2013 | CN103180730A Compositions and methods of identifying tumor specific neoantigens |
| 06/26/2013 | CN103180448A Anti-cancer adenoviruses |
| 06/26/2013 | CN103180446A Vesicular stomatitis viruses |
| 06/26/2013 | CN103180343A Composition for preventing or treating cervical cancer having human papillomavirus plasmodium and immunity enhancer |
| 06/26/2013 | CN103180322A Pyrazole compounds as jak inhibitors |
| 06/26/2013 | CN103180320A 1H-pyrrolo[2,3-b]pyridine derivatives |
| 06/26/2013 | CN103180319A Inhibitors of semicarabazide - sensitive amine oxidase |
| 06/26/2013 | CN103180314A Oxadiazole inhibitors of leukotriene production |
| 06/26/2013 | CN103180311A Compounds useful for inhibiting CHK1 |
| 06/26/2013 | CN103180309A Antagonist for mutated androgen receptor |
| 06/26/2013 | CN103180296A Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer |
| 06/26/2013 | CN103179986A Use of antibodies against nk1, nk2 and/or nk3 receptors in cancer treatment |
| 06/26/2013 | CN103179985A Antibodies that bind csf1r |
| 06/26/2013 | CN103179977A Immunotherapeutic method for treating prostate cancer |
| 06/26/2013 | CN103179968A Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics |
| 06/26/2013 | CN103179958A Method of preparing a dry powder from a water bacteria extract-concentrate |
| 06/26/2013 | CN103173529A Associated use of human NLK (Neuroleukin) gene and associated medicines |
| 06/26/2013 | CN103173522A Micromolecule nucleic acid miR-383 and diagnosis and treatment application thereof |
| 06/26/2013 | CN103173460A Allogeneic tumor therapeutic agent |
| 06/26/2013 | CN103173453A Application of lamprey Lj-RGD2 in preparation of anti-angiogenesis antitumour drug |
| 06/26/2013 | CN103173446A Construction method of recombinant adeno-associated virus vector of targeting interference SOCS1 gene and application of construction method |
| 06/26/2013 | CN103173419A Chemokine-4 resisting monoclonal antibody, chemokine-4 resisting hybridoma cell line and applications of monoclonal antibody |
| 06/26/2013 | CN103173411A Method and kit for preparing dendritic cells |
| 06/26/2013 | CN103173410A Composition and method for stimulating dendritic cell maturation |
| 06/26/2013 | CN103173357A Ceriporia lacerata and application thereof |
| 06/26/2013 | CN103173344A Tartary buckwheat vinegar and preparation process thereof |
| 06/26/2013 | CN103173338A Health care wine |